DK1543038T4 - Proteinoprensning - Google Patents

Proteinoprensning Download PDF

Info

Publication number
DK1543038T4
DK1543038T4 DK03795664.6T DK03795664T DK1543038T4 DK 1543038 T4 DK1543038 T4 DK 1543038T4 DK 03795664 T DK03795664 T DK 03795664T DK 1543038 T4 DK1543038 T4 DK 1543038T4
Authority
DK
Denmark
Prior art keywords
protein purification
purification
protein
Prior art date
Application number
DK03795664.6T
Other languages
English (en)
Other versions
DK1543038T3 (da
Inventor
Paul J Mcdonald
Rhona O'leary
Jefferson C Emery
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1543038(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK1543038T3 publication Critical patent/DK1543038T3/da
Application granted granted Critical
Publication of DK1543038T4 publication Critical patent/DK1543038T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03795664.6T 2002-09-11 2003-09-08 Proteinoprensning DK1543038T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41033402P 2002-09-11 2002-09-11
PCT/US2003/028064 WO2004024866A2 (en) 2002-09-11 2003-09-08 Protein purification

Publications (2)

Publication Number Publication Date
DK1543038T3 DK1543038T3 (da) 2017-07-10
DK1543038T4 true DK1543038T4 (da) 2020-11-09

Family

ID=31994112

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10187798.3T DK2332996T3 (da) 2002-09-11 2003-09-08 Oprensning af anti-Her2-antistoffer
DK03795664.6T DK1543038T4 (da) 2002-09-11 2003-09-08 Proteinoprensning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10187798.3T DK2332996T3 (da) 2002-09-11 2003-09-08 Oprensning af anti-Her2-antistoffer

Country Status (15)

Country Link
US (10) US8044017B2 (da)
EP (3) EP2332996B1 (da)
JP (7) JP5303092B2 (da)
AU (2) AU2003265994B2 (da)
CA (1) CA2496060C (da)
CY (1) CY1119024T1 (da)
DK (2) DK2332996T3 (da)
ES (2) ES2629602T5 (da)
HK (1) HK1158223A1 (da)
HU (1) HUE033623T2 (da)
IL (5) IL262513B (da)
LT (1) LT1543038T (da)
PT (1) PT1543038T (da)
SI (1) SI1543038T2 (da)
WO (1) WO2004024866A2 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7672730B2 (en) * 2001-03-08 2010-03-02 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
HUE033623T2 (en) * 2002-09-11 2017-12-28 Genentech Inc protein purification
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200706017B (en) * 2005-01-21 2008-12-31 Genentech Inc Fixed dosing of her antibodies
EP1850874B1 (en) * 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200714290A (en) * 2005-03-08 2007-04-16 Pharmacia & Upjohn Co Llc Anti-M-CSF antibody compositions having reduced levels of endotoxin
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20090247421A1 (en) * 2005-03-23 2009-10-01 Egisto Boschetti Diverse chemical libraries bound to small particles with paramagnetic properties
US7754861B2 (en) * 2005-03-23 2010-07-13 Bio-Rad Laboratories, Inc. Method for purifying proteins
KR20080006601A (ko) * 2005-04-11 2008-01-16 메다렉스, 인코포레이티드 단백질 정제 방법
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
FI2061803T4 (fi) 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
AU2008256411B2 (en) 2007-06-01 2013-08-22 F. Hoffmann-La Roche Ag Immunoglobulin purification
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
SG175597A1 (en) 2007-10-30 2011-11-28 Genentech Inc Antibody purification by cation exchange chromatography
CN101225102B (zh) * 2008-01-21 2013-07-31 南昌大学 罗非鱼鱼皮多肽螯合锌盐的制备方法
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102471377B (zh) 2009-07-24 2015-04-22 霍夫曼-拉罗奇有限公司 优化抗体的生产
BR112012004710A2 (pt) 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI400128B (zh) * 2009-11-30 2013-07-01 Univ Tamkang 蛋白質純化方法
EP2536748B1 (en) 2010-02-18 2014-08-20 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
CA2806314C (en) * 2010-07-30 2019-09-24 Medimmune, Llc Method for purifying active polypeptides or immunoconjugates
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
PL2616101T3 (pl) * 2010-09-14 2015-01-30 Hoffmann La Roche Sposób oczyszczania pegylowanej erytropoetyny
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
SG191186A1 (en) * 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
MX357821B (es) * 2010-12-21 2018-07-25 Hoffmann La Roche Preparación de anticuerpo enriquecida con isoforma y método para obtenerla.
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2714713B1 (en) * 2011-05-26 2018-05-09 Dr. Reddy's Laboratories Limited Purification of anti-cd20 antibodies
JP2014526891A (ja) 2011-08-17 2014-10-09 ジェネンテック， インコーポレイテッド ニューレグリン抗体とその使用
WO2013026803A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Cation and anion exchange chromatography method
DK2766040T3 (da) 2011-10-14 2019-07-22 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
RU2019103083A (ru) 2011-11-30 2019-03-22 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
WO2014118685A2 (en) * 2013-01-29 2014-08-07 Dr. Reddy's Laboratories Limited Method of altering the acidic variant content of antibody
WO2014137903A2 (en) 2013-03-08 2014-09-12 Genzyme Corporation Integrated continuous manufacturing of therapeutic protein drug substances
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
BR112015024926A2 (pt) 2013-04-16 2017-10-10 Genentech Inc composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe
CA2918052A1 (en) 2013-07-12 2015-01-15 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
SG10201809411PA (en) 2014-04-25 2018-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
US10399039B2 (en) 2014-06-25 2019-09-03 Emd Millipore Corporation Compact spiral-wound filter elements, modules and systems
SG10201901555UA (en) 2014-08-29 2019-03-28 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
CN108325391B (zh) 2014-08-29 2021-05-18 Emd 密理博公司 过滤液体进料的方法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
JP6699085B2 (ja) * 2015-03-25 2020-05-27 東ソー株式会社 Ｆｃ結合性タンパク質の精製方法
EP3290432B1 (en) * 2015-04-28 2022-03-30 Hybio Pharmaceutical Co., Ltd. High performance liquid chromatography method for polypeptide mixtures
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN109415427A (zh) 2016-07-15 2019-03-01 豪夫迈·罗氏有限公司 用于纯化聚乙二醇化的促红细胞生成素的方法
EP3570884B1 (en) 2017-01-17 2020-09-30 Genentech, Inc. Subcutaneous her2 antibody formulations
WO2018160654A2 (en) 2017-03-02 2018-09-07 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
KR20210049155A (ko) 2018-08-31 2021-05-04 젠자임 코포레이션 멸균 크로마토그래피 수지 및 제조 공정에서 이의 용도

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5028696A (en) * 1988-10-28 1991-07-02 Torres Anthony R Ion exchange and separation method
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1991002049A1 (en) * 1989-08-04 1991-02-21 Peter Grandics An integrated cell culture-protein purification system for the automated production and purification of cell culture products
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
BR9404004A (pt) * 1993-02-05 1999-05-25 Daratech Pty Ltd Poliptídeo isolado fragmento antigênico parte derivado ou análogo molécula de ácido nucléico método para reduzir o alastramento de um parasita helmíntico e composição de vacina
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6150507A (en) * 1995-03-23 2000-11-21 Biopure Corporation Method for producing a purified hemoglobin product
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
IL130061A (en) 1996-11-27 2001-09-13 Genentech Inc Affinity purification of polypeptide on protein a matrix
EP1007659B1 (en) * 1997-01-14 2007-06-27 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6 alpha & 6 beta
BRPI9910332B8 (pt) * 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
US6433144B1 (en) * 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US6451987B1 (en) * 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
US6417355B1 (en) 2001-04-11 2002-07-09 The United States Of America As Represented By The Secretary Of The Navy Geminal-dinitro-1-5 diazocine derivatives
HUE033623T2 (en) * 2002-09-11 2017-12-28 Genentech Inc protein purification
WO2014047311A1 (en) * 2012-09-19 2014-03-27 Genentech, Inc. Methods and compositions for preventing norleucine misincorporation into proteins

Also Published As

Publication number Publication date
CA2496060A1 (en) 2004-03-25
HK1158223A1 (en) 2012-07-13
EP1543038A4 (en) 2008-01-23
US10501491B2 (en) 2019-12-10
ES2527616T3 (es) 2015-01-27
EP1543038B2 (en) 2020-08-05
JP2005538176A (ja) 2005-12-15
IL257192A (en) 2018-03-29
EP3388452A3 (en) 2019-02-20
US20120065381A1 (en) 2012-03-15
US9868760B2 (en) 2018-01-16
CA2496060C (en) 2015-08-04
IL167041A (en) 2015-05-31
JP2010053154A (ja) 2010-03-11
EP1543038A2 (en) 2005-06-22
US20210130399A1 (en) 2021-05-06
JP2021138769A (ja) 2021-09-16
DK1543038T3 (da) 2017-07-10
LT1543038T (lt) 2017-07-10
US8710196B2 (en) 2014-04-29
JP2012214523A (ja) 2012-11-08
IL262513B (en) 2022-09-01
EP2332996A1 (en) 2011-06-15
AU2003265994A1 (en) 2004-04-30
US20180244715A1 (en) 2018-08-30
SI1543038T1 (sl) 2017-07-31
AU2010202784A1 (en) 2010-07-22
AU2003265994B2 (en) 2010-04-01
US20190352333A1 (en) 2019-11-21
DK2332996T3 (da) 2014-12-15
US20040082047A1 (en) 2004-04-29
WO2004024866A3 (en) 2004-10-14
US8044017B2 (en) 2011-10-25
US20190352332A1 (en) 2019-11-21
PT1543038T (pt) 2017-07-07
IL262513A (en) 2018-12-31
ES2629602T5 (es) 2021-06-08
SI1543038T2 (sl) 2020-12-31
US20190352331A1 (en) 2019-11-21
JP2019043953A (ja) 2019-03-22
HUE033623T2 (en) 2017-12-28
IL238540A0 (en) 2015-06-30
JP2017095497A (ja) 2017-06-01
IL238541A0 (en) 2015-06-30
EP2332996B1 (en) 2014-10-15
CY1119024T1 (el) 2018-01-10
ES2629602T3 (es) 2017-08-11
JP5303092B2 (ja) 2013-10-02
US20210171571A1 (en) 2021-06-10
US20150072918A1 (en) 2015-03-12
EP3388452A2 (en) 2018-10-17
WO2004024866A2 (en) 2004-03-25
US20210130398A1 (en) 2021-05-06
EP1543038B1 (en) 2017-05-31
JP2015131847A (ja) 2015-07-23
IL257192B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
DK1543038T4 (da) Proteinoprensning
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE427876T1 (de) Luftkissenboot
ATE318817T1 (de) Aza-arylpiperazine
DE50212360D1 (de) Anfahrhilfesteuerungsvorrichtung
DE50212349D1 (de) Hirurgie
ATE349458T1 (de) Etonogestrelester
EP1578774A4 (en) PROTEIN PURIFICATION
ATA1572002A (de) Managementspleisskassette
ATA4142004A (de) Trägerverbau
ATE469773T1 (de) Zugöse
ATA19152002A (de) Hubkupplung
NO20053512D0 (no) IL-8-liknende proteiner
ATE396192T1 (de) N-sulfonylaminothiazole
NO20050436D0 (no) Beta-lagnedbrytende peptider
NO20052608D0 (no) Midkinlignende protein
DE10244834B8 (de) Suszeptometer
DE50209283D1 (de) Tropfbewässerungsrohr
DE10211707A8 (de) Segmentstatormaschine
ATA16872002A (de) Zwischenstück
AT5889U3 (de) Brennholzspleisser
ATA522002A (de) Vmp-bindungsprotein
DE50203335D1 (de) Falzschwertantriebsvorrichtung
DE50207561D1 (de) Gurthöhenverstellteil